Page 9 - Gamida Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

WASHINGTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- As per Vantage Market Research, the Global Stem Cell Therapy Market has been steadily growing due to the increasing importance of medical advancements and technical developments. Both established countries like the United States and developing nations like China and India, where there is an increased emphasis on preventing chronic diseases and preserving overall health cost-efficiently, are particularly in need of effective healthcare solutions. This

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.

Gamida Cell Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 31.68 million compared to USD 18.55... -Today at 07:30 am- MarketScreener

Strong start for Omisirge® launch with significant payer coverage and number of transplant centers onboarded exceeding expectations Company continues to pursue strategic partnership to further... -Today at 07:02 am- MarketScreener

Gamida Cell Ltd. (GMDA), which recently secured FDA approval for its cell therapy Omisirge, on Monday, said that it is seeing high interest from transplant centers, exceeding its expectations.